Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8

Renal cell carcinoma (RCC) is the third most frequent malignancy within urological oncology. Sunitinib has been used as the standard of treatment for first-line RCC therapy. Understanding mechanisms of sunitinib resistance in RCC cell is important for clinical therapy and drug development. We establ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biological chemistry 2021-09, Vol.402 (10), p.1247-1256
Hauptverfasser:	Cui, Ning, Han, Qiang, Cao, Qizhen, Wang, Kejun, Zhou, Xujia, Hou, Pingzhi, Liu, Chao, Chen, Lungang, Xu, Lin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - metabolism Carcinoma, Renal Cell - pathology Dose-Response Relationship, Drug Drug development Drug Resistance, Neoplasm - drug effects Drug Screening Assays, Antitumor Embryos Humans IL-8 Indoles - pharmacology Interleukin 8 Interleukin-8 - metabolism Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - metabolism Kidney Neoplasms - pathology Lefty Malignancy NF-κB protein RCC Renal cell carcinoma Sensitivity siRNA sunitinib Sunitinib - pharmacology Transcription activation Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!